Advisors Capital Management LLC purchased a new position in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 81,937 shares of the medical research company's stock, valued at approximately $4,931,000. Advisors Capital Management LLC owned about 0.05% of Bruker at the end of the most recent reporting period.
Other institutional investors and hedge funds have also made changes to their positions in the company. Orbis Allan Gray Ltd increased its stake in Bruker by 5.4% in the fourth quarter. Orbis Allan Gray Ltd now owns 14,906,730 shares of the medical research company's stock valued at $702,256,000 after purchasing an additional 761,258 shares during the last quarter. Pallas Capital Advisors LLC acquired a new stake in Bruker during the 2nd quarter worth $570,746,000. State Street Corp lifted its position in Bruker by 2.5% in the fourth quarter. State Street Corp now owns 3,831,814 shares of the medical research company's stock valued at $180,700,000 after acquiring an additional 91,706 shares during the last quarter. AQR Capital Management LLC boosted its stake in Bruker by 125.3% in the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company's stock valued at $137,065,000 after acquiring an additional 1,850,215 shares in the last quarter. Finally, Sculptor Capital LP boosted its stake in Bruker by 9.0% in the first quarter. Sculptor Capital LP now owns 3,270,000 shares of the medical research company's stock valued at $118,112,000 after acquiring an additional 270,000 shares in the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.
Bruker Stock Up 2.2%
Shares of NASDAQ:BRKR opened at $59.92 on Friday. Bruker Corporation has a fifty-two week low of $28.53 and a fifty-two week high of $65.30. The company has a quick ratio of 0.92, a current ratio of 1.85 and a debt-to-equity ratio of 0.76. The firm's 50-day simple moving average is $58.55 and its 200-day simple moving average is $47.39. The company has a market cap of $9.13 billion, a price-to-earnings ratio of -85.60, a PEG ratio of 1.79 and a beta of 1.28.
Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 EPS for the quarter, beating analysts' consensus estimates of $0.38 by $0.11. The firm had revenue of $838.50 million during the quarter, compared to the consensus estimate of $853.57 million. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The firm's revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.32 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities research analysts predict that Bruker Corporation will post 2.12 earnings per share for the current year.
Bruker Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Monday, September 21st will be issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Monday, September 21st. Bruker's dividend payout ratio is currently -28.57%.
Analysts Set New Price Targets
Several research firms have commented on BRKR. Citigroup cut their price target on Bruker from $60.00 to $53.00 and set a "hold" rating on the stock in a research report on Wednesday, August 5th. JPMorgan Chase & Co. increased their price objective on Bruker from $55.00 to $65.00 and gave the company an "overweight" rating in a report on Monday, June 8th. Stifel Nicolaus set a $50.00 target price on shares of Bruker in a research report on Wednesday, August 5th. Guggenheim lifted their target price on shares of Bruker from $50.00 to $70.00 and gave the company a "buy" rating in a report on Monday, June 29th. Finally, Wolfe Research assumed coverage on shares of Bruker in a research report on Monday, June 1st. They issued a "peer perform" rating for the company. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $56.64.
Read Our Latest Research Report on BRKR
Bruker Company Profile
(
Free Report)
Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.
Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.
In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.
Featured Stories
Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Corporation (NASDAQ:BRKR - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Bruker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.
While Bruker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
